3. Whitehead M, Godfree AV. Hormone replacement therapy. Your Questions Answered. 1992. London: Churchill Livingstone;13–23.
4. Utian WH, Shoupe D, Bachmann G, Punkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001. 75:1065–1079.
Article
5. Crandall C. Low-dose estrogen therapy for menopausal women: A review of efficacy and safety. J Womens Health (Larchmt). 2003. 12:723–747.
Article
6. Ettinger B, Pressman A, VanGessel A. Low-dosage esterified estrogen opposed by progestin at 6-month intervals. Obstet Gynecol. 2001. 98:205–211.
7. Barnabei VM, Cochrane BB, Aragaki AK, Nygaard I, Williams S, McGovern PG, et al. Menopausal symptoms and treatment related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol. 2005. 105:1063–1073.
Article
9. Ockene JK, Barad DH, Cochrane BB. Recurrent vasomotor symptoms common for EPT users in WHI after study was discontinued. JAMA. 2005. 294:183–193.
10. Pandya KJ, Morrow GR, Roscoe JA. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 2005. 366:818–824.
Article
11. Avis NE, Brambilla D, Mckinlay SM, Vass K. A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women's Health Study. Ann Epidemiol. 1994. 4:214–220.
Article
12. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey I : lifetime prevalence, choronicity and recurrence. J Affect Disord. 1993. 29:85–96.
Article
13. Busch CM, Zonderman AB, Costa PT Jr. Menopausal transition and psychological distress in a nationally representative sample: is menopause associated with psychological distress? J Aging Health. 1994. 6:209–228.
Article
15. Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital therapy committee. Obstet Gynecol. 1998. 92:722–727.
Article
16. Johnson SR, Ettinger B, Macer JL, Ensrud KE, Quan J, Grady D. Uterine and vaginal effects of unopposed Ultralow-dose transdermal estradiol. Obstet Gynecol. 2005. 105:779–787.
Article
17. Fantl JA, Bump RC, Robinson D, McClish DK, Wyman JF. Efficacy of estrogen supplementation in the treatment of urinary incontinence. The continence program for women research group. Obstet Gynecol. 1996. 88:745–749.
18. Jackson S, Shepherd A, Brookes S, Abrams P. The effect of estrogen supplementation in the treatment of urinary incontinence. ; a double-blind placebo-controlled trial. Br J Obstet Gynaecol. 1999. 106:711–718.
Article
19. Grodstein F, Lifford K, Resnick NM, Curhan GC. Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstet Gynecol. 2004. 103:254–260.
Article
20. Stenmauer JE, Waetgen LE, Vittinghoff E, Subak LL, Hulley SB, Grady D. Postmenopausal Hormone therapy. Dose it cause incontinence? Obstet Gynecol. 2005. 106:940–945.
21. Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, Iglesia C, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA. 2005. 293:935–948.
Article
22. Waetjen LE, Brown JS, Vittinghoff E, Ensrud KE, Pinkerton J, Wallace R, et al. The effect on Ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women. Obstet Gynecol. 2005. 106:946–952.
Article
23. Hulley S, Grady D, Bush T. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998. 280:605–613.
Article
24. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002. 288:321–333.
25. Manson JE, Hsia J, Johnson KC. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003. 349:523–534.
Article
26. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hystetectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004. 291:1701–1712.
27. Clarkson TB, Anthony MS, Klein KP. Hormone replacement therapy and coronary artery ahterosclerosis: the monkey model. Br J Obstet Gynaecol. 1996. 103:Suppl 13. 53–57.
28. Clarkson TB, Anthony MS, Morgan TM. Inhibition of postmenopausal atherosclerosis progression : a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J Clin Endocrinol Metab. 2001. 86:41–47.
Article
29. Admans MR, Kaplan JR, Manuck SB. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis. 1990. 10:1051–1057.
Article
30. DeKleijin MJJ, Bots ML, Bak AA. Hormone replacement therapy in perimenopausal women and 2-year change of carotid intima-media thickness. Maturitas. 1999. 32:195–204.
Article
31. Hodis HN, Mack WJ, Lobo RA. Estrogen in the prevention of atherosclerosis : a randomized double-blind, placebo-controlled trial. Ann Int Med. 2001. 135:939–953.
32. Akhrass F, Evnas AT, Wang Y. Hormone replacement therapy is associated with less coronary atherosclerosis in postmenopausal women. J Clin Endocrinol Metab. 2003. 88:5611–5614.
Article
33. Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR. KEEPS: The Kronos early estrogen prevention study. Climacteric. 2005. 8:3–12.
Article
34. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, et al. the WHIMS Investigators. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003. 289:2663–2672.
Article
35. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ochene JK, et al. the WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003. 289:2651–2662.
Article
36. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB. Conjugated equine estrogens and global cognitive function in postmenopausal women. Womens health initiative memory study. JAMA. 2004. 291:2959–2968.
Article
37. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. the Women's Health Initiative Memory Study Investigators. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004. 291:2947–2958.
Article
38. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC. Hormone replacement therapy and incidence of Alzheimer disease in older women. The Cache County Study. JAMA. 2002. 288:2123–2129.
Article
39. Bagger YZ, Tanko LB, Alexandersen P, Qin G, Christiansen C. the PERF Study Group. Early postmenopausal hormone therapy may prevent cognitive impairment later in life. Menopause. 2005. 12:12–17.
Article
40. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy : collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997. 350:1047–1059.
41. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen replacement therapy after ischemic stroke. N Engl J Med. 2001. 345:1243–1249.
Article
42. Beral V, Reeves G, Banks E. Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women. BJOG. 2005. 112:692–695.
Article
43. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Lane GD, Rodabough RJ, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women : the Womens Health Initiative Randomized Trial. JAMA. 2003. 289:3243–3253.
Article
44. Hulley S, Furberg C, Barrett-connor E, Cauley J, Grady D, Haskell W, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA. 2002. 288:58–66.
Article
45. de Lignieres B, de Vathaire F, Fournier S, Urbinelli R, Allaert F, Le MG. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric. 2002. 5:332–340.
Article
46. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005. 114:448–454.
Article
47. Von Schoultz E, Rutqvist LE. Menopausal hormone therapy after breast cancer: the Stockholm randomized Trail. J Natl Cancer Inst. 2005. 97:533–535.
Article
48. Holmberg L, Anderson G. HABITS (hormonal replacement therapy after breast cancer- is it safe?) a randomized comparison stopped. Lancet. 2004. 363:453–455.
Article